Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6716 USD | -5.02% | -8.24% | -9.61% |
Financials (USD)
Sales 2024 * | 5.59M | Sales 2025 * | 3.67M | Capitalization | 36.71M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -66M | EV / Sales 2024 * | 4.71 x |
Net cash position 2024 * | 10.4M | Net Debt 2025 * | 29.1M | EV / Sales 2025 * | 17.9 x |
P/E ratio 2024 * |
-0.62
x | P/E ratio 2025 * |
-0.66
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.57% |
Latest transcript on Cara Therapeutics, Inc.
1 day | -5.02% | ||
1 week | -8.24% | ||
Current month | -26.20% | ||
1 month | -23.97% | ||
3 months | +26.29% | ||
6 months | -47.53% | ||
Current year | -9.61% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 18-08-05 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 22-09-11 |
Scott Terrillion
CMP | Compliance Officer | 61 | 16-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 10-06-30 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-07-15 |
Helen Boudreau
BRD | Director/Board Member | 58 | 23-08-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.20% | 35 M€ | +21.31% | - | |
1.29% | 13 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 0.6716 | -5.02% | 217,430 |
24-04-23 | 0.7071 | -3.19% | 181,920 |
24-04-22 | 0.7304 | +10.50% | 346,171 |
24-04-19 | 0.661 | -4.20% | 351,866 |
24-04-18 | 0.69 | -5.72% | 363,143 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.61% | 36.71M | |
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-21.94% | 29.36B | |
+54.37% | 24.49B | |
-5.41% | 17.31B | |
-44.23% | 11.26B | |
-17.60% | 11.62B | |
-13.96% | 11.31B | |
+7.42% | 8.31B |
- Stock Market
- Equities
- CARA Stock